SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,749.78 |
Enterprise Value ($M) | 1,680.45 |
Book Value ($M) | 1,035.73 |
Book Value / Share | 18.56 |
Price / Book | 1.69 |
NCAV ($M) | 353.73 |
NCAV / Share | 6.34 |
Price / NCAV | 4.95 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.07 |
Return on Assets (ROA) | 0.06 |
Return on Equity (ROE) | 0.08 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.16 |
Current Ratio | 2.35 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 686.07 |
Assets | 1,368.07 |
Liabilities | 332.34 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 661.82 |
Operating Income | 61.36 |
Net Income | 73.86 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 171.95 |
Cash from Investing | -189.87 |
Cash from Financing | 12.19 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | BlackRock, Inc. | 14.70 | -21.04 | |
13G/A | Armistice Capital, Llc | 8.76 | -5.10 | |
13G/A | Macquarie Group Ltd | 4.78 | -3.87 | |
13G | Dimensional Fund Advisors Lp | 5.20 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
59,511 | 306,315 | 19.43 | |
56,416 | 219,810 | 25.67 | |
104,280 | 338,697 | 30.79 | |
58,914 | 273,794 | 21.52 | |
(click for more detail) |
Similar Companies | |
---|---|
SMMT – Summit Therapeutics Inc. | SPRY – ARS Pharmaceuticals, Inc. |
STRO – Sutro Biopharma, Inc. | TARA – Protara Therapeutics, Inc. |
TBPH – Theravance Biopharma, Inc. |
Financial data and stock pages provided by
Fintel.io